Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
CADL(NASDAQ:CADL) NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel’s Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 for recurrent high-grade glioma.
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
CADLNEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in upcoming investor conferences with associated one-on-one investor meetings.
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
CADLNEEDHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the second quarter ended June 30, 2025, and provided a corporate update.
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On?
CADLCandel Therapeutics stock rose after its prostate cancer therapy, CAN-2409, received FDA RMAT designation. This expedites development and review, following positive Phase 3 trial results.
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation For CAN-2409 In Treatment Of Prostate Cancer
CADLCandel Therapeutics To Host Call Discussing CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
CADLCandel Therapeutics Announces Phase 3 CAN-2409 Results In Localized Prostate Cancer At ASCO 2025
CADLCandel Therapeutics Q1 EPS $0.13 Beats $(0.21) Estimate
CADLCandel Therapeutics Announces Oral Presentation Of Phase 3 CAN-2409 Results In Localized Prostate Cancer At ASCO 2025
CADLHC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target
CADLCandel Therapeutics Announces Publication In Neuro-Oncology Of Phase 1b Clinical Trial Data On The Combination Of CAN-2409 And Nivolumab plus Standard Of Care In Newly Diagnosed High-Grade Glioma Patients
CADLCandel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients
CADLCandel Therapeutics' CAN-2409 extended survival in NSCLC patients, with biomarker data showing enhanced response in non-squamous cases and a strong safety profile.
Candel Therapeutics Shares Are Down Today: What's Going On?
CADLCandel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409.
Candel Therapeutics Announces Final Data From Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2a Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment
CADLCandel Therapeutics And IDEA Pharma Announce Commercial Partnership, IDEA To Provide Commercial Input Throughout Candel's Development And Commercialization Process For CAN-2409
CADLHC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target
CADLCandel Therapeutics Q4 EPS $(0.40) Misses $(0.23) Estimate
CADLCanaccord Genuity Maintains Buy on Candel Therapeutics, Raises Price Target to $25
CADLHC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target
CADLCandel Therapeutics Final Survival Data From Randomized Controlled Phase 2 Clinical Trial CAN-2409 In Non-Metastatic Pancreatic Cancer Showing Improvement In Estimated Median Overall Survival Of 31.4 Months After Treatment vs 12.5 Months In Control Group
CADLCitigroup Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $25
CADLThis GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
CADLCanaccord Genuity Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $20
CADLCandel Therapeutics Announces 2025 Milestones, CAN-2409 Updates For PDAC, NSCLC In Q1 2025, BLA Submission For Prostate Cancer In Q4 2026; Phase 3 Data To Be Presented; CAN-3110 Trial Results For rHGG By Q4 2025; $103M Cash To Fund Operations Into Q1 2027
CADLHC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target
CADLCandel Therapeutics Q3 EPS $(0.33) Down From $(0.29) YoY
CADLCandel Therapeutics To Present Preclinical Results For CAN-3110 In Melanoma At SITC Annual Meeting
CADLLooking Into Candel Therapeutics's Recent Short Interest
CADL